Resource impact statement
Cancer Drugs Fund technology
NICE has recommended ibrutinib for use within the Cancer Drugs Fund for treating Waldenstrom’s macroglobulinaemia only if the conditions in the managed access agreement for ibrutinib are followed.
Ibrutinib will be available to the NHS in line with the managed access agreement with NHS England. As part of this, NHS England and Janssen have a commercial access agreement that makes ibrutinib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence.
The resource impact of ibrutinib will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date the managed access agreement expires (anticipated September 2020) or when the results of the managed access agreement data collection are available, whichever is sooner. The aim of the review is to decide whether or not the drug can be recommended for routine use. Further information can be found in NHS England’s Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) - A new deal for patients, taxpayers and industry.
It is estimated that 335 people with Waldenstrom’s macroglobulinaemia will be eligible for treatment with ibrutinib over the course of the managed access agreement.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: 22 November 2017